MedPharm, a UK-based global topical and transdermal CDMO, announced on Thursday that it has named Lynn Allen as its new chief executive officer (CEO), effective 1 January 2024.

Allen has over 25 years of experience in contract development and manufacturing services specific to topical, transdermal, and injectable delivery routes. She has served as vice president of Business Development and in a series of commercial leadership roles at DPT Laboratories and Jubilant HollisterStier.

Trevor Wahlbrink, partner, Ampersand Capital Partners, said, 'We congratulate Lynn on her appointment to CEO. Her leadership and deep knowledge of MedPharm's scientific capabilities, in addition to her strong commercial track record, will be instrumental to MedPharm's growth and expansion.'